All In Biotech

Drug Trial Radar · NCT04877691

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 367 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

367

Actual

Start

Jun 8, 2021

Primary completion

Aug 22, 2025

Study completion Nov 6, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
IQVIA Pty Ltd
First posted
May 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is evaluating the efficacy and safety of SC antifrolumab in adult patients with moderate -to-severe SLE despite receiving standard therapy

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Medi-546Drug

    Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.

  • PlaceboDrug

    Solution for injection in aPFS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responseTime frame: At week 52

Locations

140 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Paradise Valley, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    El Cajon, California

  • Research Site

    Fullerton, California

  • Research Site

    Hemet, California

  • Research Site

    La Mesa, California

  • Research Site

    Los Angeles, California

  • Research Site

    Menifee, California

  • Research Site

    Upland, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Brandon, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Flint, Michigan

  • Research Site

    Lansing, Michigan

  • Research Site

    Newark, New Jersey

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Brooklyn, New York

  • Research Site

    Manhasset, New York

  • Research Site

    New York, New York

  • Research Site

    Potsdam, New York

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Reading, Pennsylvania

  • Research Site

    Memphis, Tennessee

  • Research Site

    Grapevine, Texas

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Mendoza, Argentina

  • Research Site

    Pergamino, Argentina

  • Research Site

    Quilmes, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Salta, Argentina

Showing 40 of 140 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.